These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25438647)

  • 21. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
    Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Joint tenderness and swelling in biologic-treated inflammatory arthritis patients - a tricky trade off?
    Harty LC; Ng CT; Fearon C; Murray CA; Fitzgerald O; Veale DJ
    Int J Clin Pract; 2012 Feb; 66(2):128-31. PubMed ID: 22257038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapies for dactylitis in psoriatic arthritis. A systematic review.
    Helliwell PS
    J Rheumatol; 2006 Jul; 33(7):1439-41. PubMed ID: 16724369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving recognition of psoriatic arthritis.
    Conaghan PG; Coates LC
    Practitioner; 2009 Dec; 253(1724):15-8, 2-3. PubMed ID: 20120827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early treatment of psoriatic arthritis improves prognosis.
    McLaughlin M; Ostör A
    Practitioner; 2014 Dec; 258(1777):21-4, 3. PubMed ID: 25603589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    J Rheumatol Suppl; 2009 Aug; 83():78-80. PubMed ID: 19661551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive treatment of dactylitis in psoriatic arthritis.
    Rose S; Toloza S; Bautista-Molano W; Helliwell PS;
    J Rheumatol; 2014 Nov; 41(11):2295-300. PubMed ID: 25362714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics.
    Chimenti MS; Teoli M; Saraceno R; Dattola A; Ventura A; Chiricozzi A; Chiaramonte C; Perricone R; Chimenti S
    Dermatology; 2013; 227(4):305-10. PubMed ID: 24280959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the treatment of peripheral arthritis in psoriatic arthritis.
    Soriano ER; Rosa J
    Curr Rheumatol Rep; 2009 Aug; 11(4):270-7. PubMed ID: 19691930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
    Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
    J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.